Point72 Asset Management Discloses 1.7% Stake in Vera Therapeutics, Inc.

On April 1, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a Schedule 13G regarding their holdings in Vera Therapeutics, Inc. (VERA). The filing discloses a combined beneficial ownership of 1,229,525 shares of Class A Common Stock, representing 1.7% of the class. This position includes 17,800 shares issuable upon the exercise of call options. The reporting persons indicated that on the event date of March 25, 2026, they may have been deemed beneficial owners of more than 5% of the company's stock, triggering the filing requirement; however, as of the filing date, their ownership has adjusted to the reported 1.7%. Point72 Asset Management maintains investment and voting power over the shares held by its managed investment funds, with Point72 Capital Advisors serving as the general partner and Steven A. Cohen exercising control over both entities. The filing is a passive investment certification, indicating the shares were not acquired to influence or change control of the issuer.